Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lacosamide
Drug ID BADD_D01238
Description Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.
Indications and Usage Lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.
Marketing Status Prescription
ATC Code N03AX18
DrugBank ID DB06218
KEGG ID D07299
MeSH ID D000078334
PubChem ID 219078
TTD Drug ID D05OFX
NDC Product Code 66689-108; 52038-005; 36998-1810; 27808-245; 50228-195; 69539-026; 36998-2477; 67877-733; 68462-678; 14445-012; 65977-0075; 14445-130; 50370-0024; 36998-2478; 68462-681; 65162-925; 47335-922; 69539-025; 0131-5410; 51991-349; 51991-350; 65162-924; 0131-1810; 62331-062; 69539-027; 51991-351; 36998-0119; 36998-2480; 65862-720; 66689-107; 50228-194; 27808-246; 31722-815; 0131-2479; 62332-172; 51991-348; 46708-860; 50228-192; 31722-814; 53296-0101; 0904-7247; 14445-129; 0904-7245; 68462-679; 66689-109; 50228-193; 36998-2479; 17205-107; 25021-791; 13612-0021; 65162-926; 62332-173; 0131-2477; 31722-812; 62332-171; 66651-914; 70166-617; 16436-0101; 67877-735; 14445-406; 14445-132; 66039-882; 67877-736; 0904-7246; 14445-021; 69539-028; 17180-2746; 27808-243; 62332-174; 67877-734; 31722-813; 47335-980; 65372-1186; 0131-2480; 47335-943; 66689-110; 0904-7244; 68225-057; 14445-131; 68462-680; 53747-069; 47335-918; 0131-2478; 27808-244; 12828-0087; 65162-923
Synonyms Lacosamide | Vimpat | N-benzyl-2-acetamido-3-methoxypropionamide | N benzyl 2 acetamido 3 methoxypropionamide | N-benzyl-AcMeOPrNH2 | N benzyl AcMeOPrNH2
Chemical Information
Molecular Formula C13H18N2O3
CAS Registry Number 175481-36-4
SMILES CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hemiparesis17.01.04.0010.006704%
Hepatic cirrhosis09.01.04.0010.001749%Not Available
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.006704%Not Available
Hepatic failure09.01.03.0020.003498%
Hepatic function abnormal09.01.02.0010.010056%Not Available
Hepatitis09.01.07.0040.010056%Not Available
Hepatitis C11.05.06.004; 09.01.09.0050.006704%Not Available
Hepatitis cholestatic09.01.01.0020.020111%Not Available
Hepatitis viral11.05.04.011; 09.01.09.007--
Hepatocellular injury09.01.07.0080.030167%Not Available
Hunger14.03.02.012; 08.01.09.0030.010056%Not Available
Hyperammonaemia14.10.01.001; 09.01.02.0020.006704%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypernatraemia14.05.04.0010.006704%
Hypersensitivity10.01.03.003--
Hypersomnia19.02.05.001; 17.15.01.0010.006704%
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Hypokalaemia14.05.03.0020.013408%
Hyponatraemia14.05.04.0020.036871%
Hypotension24.06.03.002--
Hypothermia12.05.03.001; 08.05.01.0030.010056%
Ileus07.13.01.0010.006704%
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Intentional self-injury19.12.01.002; 12.01.08.0360.020111%Not Available
Intestinal obstruction07.13.01.0020.001749%Not Available
Irritability19.04.02.013; 08.01.03.0110.040223%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 12 Pages